Need Growing EPS And Dividends? Prescribe Sanofi
Seeking Alpha
March 6, 2026
Sanofi's robust growth is driven by blockbuster drugs like Dupixent and a strong pipeline, supporting consensus EPS growth. Learn why SNY stock is a buy.
Verticals
financemarkets
Originally published on Seeking Alpha on 3/6/2026